Consensus Statement: Journal of Cystic Fibrosis
Synopsis: The consensus statement characterizes RELiZORB as a “physiologically superior product,” with “proven success in a real-world setting,” which “can produce measurable, clinically relevant benefits.” The statement further observed that, “despite its effectiveness and intuitive sense, RELiZORB is frequently unavailable to patients due to the vicissitudes of insurance approvals in the US.” This lack of access prompted the authors to develop an independently prepared consensus statement to highlight these patient challenges.
Read the Latest Published Study on Longer Term Use of RELiZORB
Additional RELiZORB Studies and Articles